alexa Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.


Journal of Antivirals & Antiretrovirals

Author(s): Colonno R, Rose R, McLaren C, Thiry A, Parkin N,

Abstract Share this page

Abstract Atazanavir (ATV) is a once-daily human immunodeficiency virus (HIV) protease inhibitor (PI) shown to be effective and well tolerated. ATV has a distinct resistance profile relative to other PIs, with susceptibility maintained against 86\% of isolates resistant to 1-2 PIs. Clinical isolates obtained from PI-naive patients designated as experiencing virologic failure while receiving ATV-containing regimens contained a unique isoleucine-to-leucine substitution at amino acid residue 50 (I50L) of the HIV-1 protease. The I50L substitution, observed in all isolates exhibiting phenotypic resistance to ATV, emerged in a variety of different backgrounds and was most frequently accompanied by A71V, K45R, and/or G73S. Viruses containing an I50L substitution were growth impaired, displayed ATV-specific resistance, and had increased susceptibilities (
  • DOI: 10.1086/386291
  • This article was published in J Infect Dis and referenced in Journal of Antivirals & Antiretrovirals

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Peer Reviewed Journals
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version